Key features and details
- Detection method: Fluorescent
- Platform: Microplate reader
- Sample type: Plasma, Serum
Product nameParaoxonase 1 Activity Assay Kit
See all PON1 kits
Sample typeSerum, Plasma
Paraoxonase 1 Activity Assay Kit (ab241044) enables rapid measurement of Paraoxonase 1 (PON1) activity, utilizing a fluorogenic substrate that is converted into a highly fluorescent product (Ex/Em = 368/460 nm). This ensures dramatically greater sensitivity than UV or colorimetric assays and eliminates the need for dangerous toxic substrates. A selective PON1 inhibitor is provided for verification of PON1 specific activity. The assay is simple to perform, high-throughput adaptable and can detect a minimum of 2.0 μU paraoxonase activity with a sample volume of 5 μL.
Storage instructionsStore at -20°C. Please refer to protocols.
Components 100 tests Fluorescence Standard 1 vial Paraoxonase Assay Buffer 1 x 50ml Paraoxonase Positive Control 1 vial PON1 Inhibitor (2-hydroxyquinoline) 1 vial PON1 Substrate 1 vial
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
FunctionHydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.
Tissue specificityPlasma, associated with HDL (at protein level). Expressed in liver, but not in heart, brain, placenta, lung, skeletal muscle, kidney or pancreas.
Involvement in diseaseGenetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5) [MIM:612633]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Note=Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients.
Sequence similaritiesBelongs to the paraoxonase family.
The signal sequence is not cleaved.
Present in two forms, form B contains a disulfide bond, form A does not.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
- A esterase 1
- A-esterase 1
- Aromatic esterase 1
Standard curve of PON1 Substrate metabolite fluorescence. One mole of fluorescence standard corresponds to the metabolism of one mole of PON1 Substrate.
Reaction kinetics of PON1 Substrate metabolism in donor-pooled human serum (5 µL), donor-pooled human plasma (5 µL) and rabbit serum (2.5 µL) in the presence and absence of 200 µM of the selective PON1 inhibitor 2- hydroxyquinoline (no inhibitor conditions contained 0.4% DMSO as a solvent control).
Quantification of PON1 activity in serum/plasma samples (mean ± SEM of four independent replicates). Assays were performed according to the kit protocol.
ab241044 has not yet been referenced specifically in any publications.